Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$26.45
-1.9%
$28.23
$25.17
$36.45
$4.37B0.531.79 million shs992,596 shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$165.71
0.0%
$146.09
$93.58
$169.49
$3.25B0.96149,753 shs138,443 shs
MannKind Corporation stock logo
MNKD
MannKind
$5.36
-3.9%
$4.19
$3.38
$7.63
$1.71B1.022.76 million shs4.37 million shs
Repligen Corporation stock logo
RGEN
Repligen
$113.70
+0.1%
$120.73
$102.96
$182.52
$6.39B1.07771,698 shs312,084 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
0.00%-9.92%-7.16%-8.33%-2.49%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
0.00%-0.60%+9.71%+44.12%+58.20%
MannKind Corporation stock logo
MNKD
MannKind
0.00%+0.54%+49.33%+46.19%-11.16%
Repligen Corporation stock logo
RGEN
Repligen
0.00%-8.85%-8.69%-9.95%-18.89%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$26.45
-1.9%
$28.23
$25.17
$36.45
$4.37B0.531.79 million shs992,596 shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$165.71
0.0%
$146.09
$93.58
$169.49
$3.25B0.96149,753 shs138,443 shs
MannKind Corporation stock logo
MNKD
MannKind
$5.36
-3.9%
$4.19
$3.38
$7.63
$1.71B1.022.76 million shs4.37 million shs
Repligen Corporation stock logo
RGEN
Repligen
$113.70
+0.1%
$120.73
$102.96
$182.52
$6.39B1.07771,698 shs312,084 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
0.00%-9.92%-7.16%-8.33%-2.49%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
0.00%-0.60%+9.71%+44.12%+58.20%
MannKind Corporation stock logo
MNKD
MannKind
0.00%+0.54%+49.33%+46.19%-11.16%
Repligen Corporation stock logo
RGEN
Repligen
0.00%-8.85%-8.69%-9.95%-18.89%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alkermes plc stock logo
ALKS
Alkermes
2.92
Moderate Buy$41.8558.21% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
3.00
Buy$176.506.51% Upside
MannKind Corporation stock logo
MNKD
MannKind
3.17
Buy$11.17108.53% Upside
Repligen Corporation stock logo
RGEN
Repligen
2.67
Moderate Buy$166.6746.59% Upside

Current Analyst Ratings Breakdown

Latest MNKD, RGEN, ALKS, and LGND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/12/2025
Repligen Corporation stock logo
RGEN
Repligen
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetHold$145.00 ➝ $135.00
9/9/2025
Alkermes plc stock logo
ALKS
Alkermes
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$43.00
9/9/2025
Alkermes plc stock logo
ALKS
Alkermes
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$34.00 ➝ $35.00
9/9/2025
Alkermes plc stock logo
ALKS
Alkermes
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$46.00
9/5/2025
MannKind Corporation stock logo
MNKD
MannKind
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$12.00 ➝ $15.00
9/3/2025
Alkermes plc stock logo
ALKS
Alkermes
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/3/2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$167.00 ➝ $190.00
9/3/2025
MannKind Corporation stock logo
MNKD
MannKind
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$9.00 ➝ $10.00
9/3/2025
Repligen Corporation stock logo
RGEN
Repligen
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$180.00
9/2/2025
Repligen Corporation stock logo
RGEN
Repligen
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$205.00
9/2/2025
Alkermes plc stock logo
ALKS
Alkermes
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$44.00
(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alkermes plc stock logo
ALKS
Alkermes
$1.51B2.90$2.60 per share10.17$9.05 per share2.92
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$187.58M17.31$1.61 per share103.15$43.95 per share3.77
MannKind Corporation stock logo
MNKD
MannKind
$301.74M5.45$0.13 per share40.13($0.29) per share-18.47
Repligen Corporation stock logo
RGEN
Repligen
$673.96M9.49$3.11 per share36.55$35.21 per share3.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alkermes plc stock logo
ALKS
Alkermes
$367.07M$2.0812.7219.311.5223.15%24.86%17.14%10/23/2025 (Estimated)
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-$4.03M-$4.00N/A44.66N/A-40.44%-9.21%-8.09%11/6/2025 (Estimated)
MannKind Corporation stock logo
MNKD
MannKind
$27.59M$0.1148.6923.28N/A10.87%-32.60%7.81%11/6/2025 (Estimated)
Repligen Corporation stock logo
RGEN
Repligen
-$25.51M-$0.25N/A48.182.09-2.05%4.61%3.24%11/11/2025 (Estimated)

Latest MNKD, RGEN, ALKS, and LGND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.54$1.60+$0.06$0.24$43.87 million$47.63 million
8/6/2025Q2 2025
MannKind Corporation stock logo
MNKD
MannKind
$0.04$0.05+$0.01N/A$77.82 million$76.53 million
7/29/2025Q2 2025
Alkermes plc stock logo
ALKS
Alkermes
$0.42$0.52+$0.10$0.52$343.20 million$390.66 million
7/29/2025Q2 2025
Repligen Corporation stock logo
RGEN
Repligen
$0.40$0.37-$0.03$0.26$174.62 million$182.37 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
Repligen Corporation stock logo
RGEN
Repligen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alkermes plc stock logo
ALKS
Alkermes
N/A
3.23
2.85
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/A
5.45
5.21
MannKind Corporation stock logo
MNKD
MannKind
N/A
2.50
2.24
Repligen Corporation stock logo
RGEN
Repligen
0.26
8.59
7.32

Institutional Ownership

CompanyInstitutional Ownership
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
91.28%
MannKind Corporation stock logo
MNKD
MannKind
49.55%
Repligen Corporation stock logo
RGEN
Repligen
97.64%

Insider Ownership

CompanyInsider Ownership
Alkermes plc stock logo
ALKS
Alkermes
4.40%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
7.00%
MannKind Corporation stock logo
MNKD
MannKind
2.70%
Repligen Corporation stock logo
RGEN
Repligen
1.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alkermes plc stock logo
ALKS
Alkermes
1,800165.08 million157.82 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
8019.60 million18.23 millionOptionable
MannKind Corporation stock logo
MNKD
MannKind
400306.83 million297.62 millionOptionable
Repligen Corporation stock logo
RGEN
Repligen
1,77856.26 million55.58 millionOptionable

Recent News About These Companies

Woodline Partners LP Buys New Shares in Repligen Corporation $RGEN
Why Repligen (RGEN) Stock Is Down Today
RBC Capital Reaffirms Their Buy Rating on Repligen (RGEN)
Repligen (NASDAQ:RGEN) Given "Buy" Rating at HC Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alkermes stock logo

Alkermes NASDAQ:ALKS

$26.45 -0.52 (-1.93%)
As of 02:37 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$165.70 -0.05 (-0.03%)
As of 02:37 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

MannKind stock logo

MannKind NASDAQ:MNKD

$5.36 -0.21 (-3.68%)
As of 02:37 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Repligen stock logo

Repligen NASDAQ:RGEN

$113.49 -0.05 (-0.04%)
As of 02:37 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.